Overview

Pharmacokinetic and Tolerance Study of Meloxicam Eye Drops in Healthy Volunteers

Status:
Active, not recruiting
Trial end date:
2020-07-01
Target enrollment:
0
Participant gender:
All
Summary
The pharmacokinetics, safety, and tolerability of meloxicam eye drops in Chinese healthy volunteers were evaluated to provide a basis for the formulation of a phase II clinical trial dosing regimen for this product. Including pre-tests and formal trials, formal trials include single-dose pharmacokinetics tests and multiple-dose tolerance tests (4 times a day for 3 consecutive days).
Phase:
Phase 1
Accepts Healthy Volunteers?
Accepts Healthy Volunteers
Details
Lead Sponsor:
Beijing Tongren Hospital
Treatments:
Meloxicam
Ophthalmic Solutions
Criteria
Inclusion Criteria:

- Voluntarily participate in this trial and sign the informed consent before the trial;

- Age: 18 to 45 years old (including 18 and 45 years old) healthy subjects, both male
and female;

- Weight and body mass index: female subjects weigh ≥45.0kg and male subjects weigh
≥50.0kg,BMI is in the range of 19 ~ 26 kg / m2 (including 19 and 26);

- Physical examination, vital signs, laboratory examination and ECG examination during
the screening period are normal or different Often without clinical significance;

- The corrected visual acuity of both eyes should be ≥1.0. The intraocular pressure,
slit lamp, and fundus examination are normal or abnormal. It has no clinical
significance. The target eye SchirmerⅠ test result during the screening period is ≥10
mm;

- Subjects were able to communicate well with the researcher and understood and were
willing to comply with the requirements of this study.

Exclusion Criteria:

- Allergic constitution, allergic diseases or known allergies to research drugs /
similar drugs;

- Past or current suffering from circulatory system, respiratory system, digestive
system, blood system,Menstrual system, immune system, urinary system, endocrine
system, and mental illness may be significant Any condition that affects the
absorption, distribution, metabolism, and excretion of the drug or affects the safety
of the subject;

- People with eye diseases, including history of internal eye surgery or laser surgery;

- Infection screening is abnormal and clinically significant;

- Used any medicine in the last 2 weeks;

- Underwent surgery within 4 weeks prior to the trial, or plan to perform surgery within
2 weeks of the end of the study surgeon;

- Those who need to wear contact lenses during the trial;

- A history of substance abuse, or a positive urine test for substance abuse(Ketamine,
morphine, methamphetamine, dimethylene oxyamphetamine, tetrahydrocannabinol);

- Women with a positive blood pregnancy test; women who have not taken effective
contraception in the last month,Pregnant and lactating women; women and men of
childbearing age who cannot take effective contraception during the trial and within
six months after the trial is over;

- Smokers and alcoholics (smokers on average more than 5 cigarettes / day, alcohol
consumption on average 2 units / day, 1unit = 10 mL of ethanol, ie 1 unit = 200 mL of
beer with 5% alcohol or 25mL of white wine with 40% alcohol or 83mL of wine with 12%
alcohol) or a positive breath test, or during the study Stop using any tobacco
products and not stop alcohol intake;

- Those who donated more than 200 mL of blood in the 90 days before the test, or lost
blood of more than 200 mL for other reasons;

- Participants in any other clinical trials within 90 days before screening;

- Subjects refused to discontinue any use of methyl groups 48 hours before the end of
the study until the end of the study xanthine drinks or foods, such as caffeine
(coffee, tea, cola, chocolate, etc.), and beverages containing grapefruit;

- Any other condition that the investigator considers inappropriate.